Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Launched by JIANFENG ZHOU · Oct 7, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. The study aims to evaluate the safety and effectiveness of a combination of three medications: mitoxantrone hydrochloride liposome, rituximab, and lenalidomide. It is designed for adults aged 60 to 75 years who have had their DLBCL return after initial treatment or have not responded well to previous therapies. To participate, individuals must have a confirmed diagnosis of this specific lymphoma and meet certain health criteria, such as having a minimum level of blood cells and proper liver and kidney function.

Participants in this study will receive close monitoring throughout the trial to track how well the treatment works and any side effects they may experience. It’s important to note that this trial is not yet recruiting participants, so individuals interested in joining will need to wait until it starts. Additionally, there are specific health conditions and previous treatments that may prevent someone from participating, which will be reviewed by the study team. Overall, this trial offers a potential new option for individuals dealing with this challenging type of cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1.Subjects fully understand and voluntarily participate in this study and sign the informed consent form (ICF);
• • 2.60-75 years old;
• • 3.Expected survival ≥ 3 months;
• • 4.Subjects with histologically confirmed diagnosis of relapsed and refractory diffuse large B-cell lymphoma who have received at least 4 cycles of first-line chemotherapy including rituximab and anthracyclines; Relapsed lymphoma is defined as the lymphoma that relapse after obtaining complete response (CR) after initial chemotherapy; Refractory lymphoma subjects meet one of the following conditions: 1) The tumor shrinks \<50% or disease progression after 4 cycles of standard chemotherapy,; 2) CR after standard chemotherapy, but relapse within half a year; 3) 2 or more relapses after CR; 4) relapse after hematopoietic stem cell transplantation;
• • 5.Subjects who are not eligible for transplantation or do not plan to undergo transplantation at the beginning of the study;
• • 6.ECOG Performance Status: 0-2;
• • 7.Subjects must have at least one evaluable or measurable lesion per lugano2014 criteria: for lymph node lesions, the length should be \> 1.5cm; For non-lymph node lesions, the length should be \> 1.0cm;
• • 8.Bone marrow function: Absolute neutrophil count ≥1.5×109/L, Platelet count ≥75×109/L, Hemoglobin ≥ 80g/L (Absolute neutrophil can be relaxed to ≥ 1.0×109/L, Platelet count can be relaxed to ≥50×109/L, Hemoglobin can be relaxed to ≥75 g/L in subjects with poor bone-marrow reserve);
• • 9.Liver and kidney function: serum creatinine ≤ 1.5×ULN (upper limit of normal); AST and ALT ≤ 2.5×ULN (≤ 5×ULN for subjects with liver metastases); total bilirubin ≤ 1.5×ULN (≤ 3×ULN for subjects with liver metastases).
• Exclusion Criteria:
• * 1. The subject had previously received any of the following anti-tumor treatments:
• • 1. Subjects who have been treated with mitoxantrone or mitoxantrone liposomes;
• • 2. Previously received doxorubicin or other anthracycline treatment, and the total cumulative dose of doxorubicin was more than 360 mg/m2 (1 mg doxorubicin equivalent to 2 mg epirubicin);
• • 3. Subjects who received anti-tumor treatment (including chemotherapy, targeted therapy, glucocorticoid, traditional Chinese medicine with anti-tumor activity, etc.) or participated in other clinical trials and received trial drugs within 4 weeks or 5 T1/2s before the first administration of the study drugs;
• • 4. Subjects who received lenalidomide.
• • 2.Subjects with refractory lymphoma meet one of the following criteria: 1) Tumors assessed as SD/PD after ≥2 lines of chemotherapy; 2) Subjects relapse within 6 months after transplantation.
• • 3.Hypersensitivity to any study drug or its components;
• • 4.Uncontrolled systemic diseases (such as active infection, uncontrolled hypertension, diabetes, etc.)
• * 5.Heart function and disease meet one of the following conditions:
• • 1. Long QTc syndrome or QTc interval \> 480 ms;
• • 2. Complete left bundle branch block, grade II or III atrioventricular block;
• • 3. Serious and uncontrolled arrhythmias requiring drug treatment;
• • 4. New York Heart Association grade ≥ III;
• • 5. Cardiac ejection fraction (LVEF)\< 50%;
• • 6. A history of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or ECG evidence of acute ischemia or active conduction system abnormalities within 6 months before recruitment.
• • 6.Hepatitis B and hepatitis C active infection (plus HBV DNA if one positive for hepatitis B surface antigen or core antibody and HBV DNA more than 1×103 copy/mL excluded; plus HCV RNA if hepatitis C antibody positive and HCV RNA more than 1×103 copy/mL exclude)
• • 7.Baseline B-type pro-brain natriuretic peptide (NT-proBNP) \> 1800pg/ml, troponin I (cTnI) \> ULN of our center, and the retest data is still higher than the above range after three days;
• • 8.Human immunodeficiency virus (HIV) infection (HIV antibody positive);
• • 9.Subjects with other malignant tumors past or present (except for non-melanoma skin basal cell carcinoma, breast/cervical carcinoma in control, and other malignant tumors that have been effectively controlled without treatment within the past five years);
• • 10.Subjects suffering from primary or secondary central nervous system (CNS) lymphoma or a history of CNS lymphoma at the time of recruitment;
• • 11.Unsuitable subjects for this study determined by the investigator.